{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T09:53:48Z","timestamp":1776938028257,"version":"3.51.4"},"reference-count":28,"publisher":"BMJ","issue":"3","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Eur J Hosp Pharm"],"accepted":{"date-parts":[[2025,5,27]]},"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1136\/ejhpharm-2024-004452","type":"journal-article","created":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T02:50:16Z","timestamp":1749610216000},"page":"224-231","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Retrospective study of plasma anti-Xa levels in renally impaired patients receiving reduced or non-reduced therapeutic doses of dalteparin"],"prefix":"10.1136","volume":"33","author":[{"given":"Katia Christina","family":"Pires","sequence":"first","affiliation":[{"name":"Hospital Pharmacy, Maasstad Hospital, Rotterdam, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4133-2370","authenticated-orcid":false,"given":"Lieke","family":"Mitrov-Winkelmolen","sequence":"additional","affiliation":[{"name":"Hospital Pharmacy, Maasstad Hospital, Rotterdam, Netherlands"},{"name":"Hospital Pharmacy, Ikazia Hospital, Rotterdam, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8027-3778","authenticated-orcid":false,"given":"Hoang Lan","family":"Le","sequence":"additional","affiliation":[{"name":"Hospital Pharmacy, Maasstad Hospital, Rotterdam, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rogier A M","family":"Quax","sequence":"additional","affiliation":[{"name":"Internal Medicine, Maasstad Hospital, Rotterdam, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rikje","family":"Ruiter","sequence":"additional","affiliation":[{"name":"Internal Medicine, Maasstad Hospital, Rotterdam, Netherlands"},{"name":"Erasmus MC University Medical Center Rotterdam, Rotterdam, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marieke","family":"Wabbijn","sequence":"additional","affiliation":[{"name":"Internal Medicine, Ikazia Hospital, Rotterdam, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T Martijn","family":"Kuijper","sequence":"additional","affiliation":[{"name":"Science Board, Maasstad Hospital, Rotterdam, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tessa","family":"Bosch","sequence":"additional","affiliation":[{"name":"Hospital Pharmacy, Maasstad Hospital, Rotterdam, Netherlands"},{"name":"Clinical Pharmacology & Toxicology Maastad Lab, Maasstad Hospital, Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,6,10]]},"reference":[{"key":"2026042302151375000_33.3.224.1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.2005.25.6.817"},{"key":"2026042302151375000_33.3.224.2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11239-015-1314-3","article-title":"Pharmacology of anticoagulants used in the treatment of venous thromboembolism","volume":"41","author":"Nutescu","year":"2016","journal-title":"J Thromb Thrombolysis"},{"key":"2026042302151375000_33.3.224.3","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/bs.pmbts.2019.02.003","article-title":"Low molecular weight heparins and their clinical applications","volume":"163","author":"Hao","year":"2019","journal-title":"Prog Mol Biol Transl Sci"},{"key":"2026042302151375000_33.3.224.4","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s11239-019-01920-y","article-title":"Description of anti-Xa monitoring practices during low molecular weight heparin use","volume":"48","author":"Lin","year":"2019","journal-title":"J Thromb Thrombolysis"},{"key":"2026042302151375000_33.3.224.5","first-page":"360","article-title":"Dalteparin and anti-Xa: a complex interplay of therapeutic drug monitoring","volume":"77","author":"van Bergen","year":"2019","journal-title":"Neth J Med"},{"key":"2026042302151375000_33.3.224.6","first-page":"799","article-title":"College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: the clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban","volume":"122","author":"Laposata","year":"1998","journal-title":"Arch Pathol Lab Med"},{"key":"2026042302151375000_33.3.224.7","unstructured":"Federatie Medisch Specialisten . Richtlijn antitrombotisch beleid - behandeling vte met lmwh bij nierfunctiestoornissen. 2021. Available: https:\/\/richtlijnendatabase.nl\/richtlijn\/antitrombotisch_beleid\/therapie_vte\/behandeling_vte_met_lmwh_bij_nierfunctiestoornissen.html"},{"key":"2026042302151375000_33.3.224.8","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s00228-015-1880-5","article-title":"A systematic review on the accumulation of prophylactic dosages of low-molecular-weight heparins (LMWHs) in patients with renal insufficiency","volume":"71","author":"Atiq","year":"2015","journal-title":"Eur J Clin Pharmacol"},{"key":"2026042302151375000_33.3.224.9","doi-asserted-by":"crossref","first-page":"438","DOI":"10.4414\/smw.2009.11284","article-title":"Low-molecular-weight heparin in patients with renal insufficiency","volume":"139","author":"Schmid","year":"2009","journal-title":"Swiss Med Wkly"},{"key":"2026042302151375000_33.3.224.10","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-144-9-200605020-00011"},{"key":"2026042302151375000_33.3.224.11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2009.03556.x"},{"key":"2026042302151375000_33.3.224.12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0239222","article-title":"Dosage reduction of low weight heparin in patients with renal dysfunction: Effects on anti-Xa levels and clinical outcomes","volume":"15","author":"Hornung","year":"2020","journal-title":"PLoS One"},{"key":"2026042302151375000_33.3.224.13","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/s11606-015-3466-4","article-title":"Treatment with Dalteparin is Associated with a Lower Risk of Bleeding Compared to Treatment with Unfractionated Heparin in Patients with Renal Insufficiency","volume":"31","author":"Park","year":"2016","journal-title":"J Gen Intern Med"},{"key":"2026042302151375000_33.3.224.14","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1007\/s00228-022-03344-9","article-title":"Therapeutically dosed low molecular weight heparins in renal impairment: a nationwide survey","volume":"78","author":"Jaspers","year":"2022","journal-title":"Eur J Clin Pharmacol"},{"key":"2026042302151375000_33.3.224.15","unstructured":"KNMP Kennisbank . Dalteparine nierfunctie. 2020. Available: https:\/\/kennisbank.knmp.nl\/"},{"key":"2026042302151375000_33.3.224.16","doi-asserted-by":"publisher","DOI":"10.1378\/chest.126.3_suppl.188S"},{"key":"2026042302151375000_33.3.224.17","unstructured":"Pfizer Limited . Fragmin 10,000 iu\/0.4ml solution for injection - summary of product characteristics. 2020. Available: www.pfizermedicalinformation.co.uk"},{"key":"2026042302151375000_33.3.224.18","unstructured":"UpToDate Inc . Suggested dose adjustments of low molecular weight (LMW) heparins in adults with renal insufficiency. 2025. Available: www.uptodate.com"},{"key":"2026042302151375000_33.3.224.19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2009.03678.x"},{"key":"2026042302151375000_33.3.224.20","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s40262-023-01213-x","article-title":"Pharmacokinetic Alterations Associated with Critical Illness","volume":"62","author":"Morales Castro","year":"2023","journal-title":"Clin Pharmacokinet"},{"key":"2026042302151375000_33.3.224.21","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s40262-022-01202-6","article-title":"Low and Highly Variable Exposure to Prophylactic LMWH Nadroparin in Critically Ill Patients: Back to the Drawing Board for Prophylactic Dosing?","volume":"62","author":"Diepstraten","year":"2023","journal-title":"Clin Pharmacokinet"},{"key":"2026042302151375000_33.3.224.22","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1111\/bcp.15208","article-title":"Effects of dalteparin on anti-Xa activities cannot be predicted in critically ill COVID-19 patients","volume":"88","author":"van der Heijden","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"2026042302151375000_33.3.224.23","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/2162-3619-2-21","article-title":"Tinzaparin and other low-molecular-weight heparins: what is the evidence for differential dependence on renal clearance?","volume":"2","author":"Johansen","year":"2013","journal-title":"Exp Hematol Oncol"},{"key":"2026042302151375000_33.3.224.24","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2020-002262"},{"key":"2026042302151375000_33.3.224.25","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000145014.80714.35"},{"key":"2026042302151375000_33.3.224.26","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2012.01.020"},{"key":"2026042302151375000_33.3.224.27","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1080\/17512433.2022.2132228","article-title":"Critical appraisal of evidence for anti-Xa monitoring and dosing of low-molecular-weight heparin in renal insufficiency","volume":"15","author":"van den Broek","year":"2022","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2026042302151375000_33.3.224.28","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003603"}],"container-title":["European Journal of Hospital Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ejhpharm-2024-004452","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T09:16:26Z","timestamp":1776935786000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejhp.bmj.com\/lookup\/doi\/10.1136\/ejhpharm-2024-004452"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,10]]},"references-count":28,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,4,23]]},"published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1136\/ejhpharm-2024-004452"],"URL":"https:\/\/doi.org\/10.1136\/ejhpharm-2024-004452","relation":{},"ISSN":["2047-9956","2047-9964"],"issn-type":[{"value":"2047-9956","type":"print"},{"value":"2047-9964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,10]]}}}